Middle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled study

Basit Öğe Kaydı
dc.authoridMirioglu, Safak/0000-0003-0362-8154
dc.authoridGok Oguz, Ebru/0000-0002-2606-3865
dc.authoridGul, Cuma Bulent/0000-0003-2467-9356
dc.authoridOto, Ozgur Akin/0000-0003-0928-8103
dc.authoridARICI, Mustafa/0000-0002-4055-7896
dc.authoridOZER, Hakan/0000-0001-9174-0351
dc.authoridAri, Elif/0000-0001-9208-7972
dc.contributor.authorOto, Ozgur Akin
dc.contributor.authorOzturk, Savas
dc.contributor.authorArici, Mustafa
dc.contributor.authorVelioglu, Arzu
dc.contributor.authorDursun, Belda
dc.contributor.authorGuller, Nurana
dc.contributor.authorSahin, Idris
dc.date.accessioned2025-01-27T21:13:30Z
dc.date.available2025-01-27T21:13:30Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. Method The primary endpoint was death in the third month. Secondary endpoints were ongoing respiratory symptoms, need for home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary tract infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, cytomegalovirus (CMV) infection/disease and BK viruria/viremia at 3 months. Results A total of 944 KTR from 29 different centers were included in this study (523 patients in the COVID-19 group; 421 patients in the control group). The mean age was 46 +/- 12 years (interquartile range 37-55) and 532 (56.4%) of them were male. Total number of deaths was 8 [7 (1.3%) in COVID-19 group, 1 (0.2%) in control group; P = 0.082]. The proportion of patients with ongoing respiratory symptoms [43 (8.2%) versus 4 (1.0%); P Conclusion The prevalence of ongoing respiratory symptoms increased in the first 3 months post-COVID in KTRs who have recovered from COVID-19, but mortality was not significantly different.
dc.identifier.doi10.1093/ckj/sfac045
dc.identifier.endpage1006
dc.identifier.issn2048-8505
dc.identifier.issn2048-8513
dc.identifier.issue5
dc.identifier.pmid35498893
dc.identifier.scopus2-s2.0-85142620316
dc.identifier.scopusqualityQ1
dc.identifier.startpage999
dc.identifier.urihttps://doi.org/10.1093/ckj/sfac045
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28441
dc.identifier.volume15
dc.identifier.wosWOS:000768374700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofClinical Kidney Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectCOVID-19
dc.subjectkidney transplantation
dc.subjectmortality
dc.subjectoutcome
dc.subjectregistry
dc.titleMiddle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu